Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02014844 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT02014844 is a Phase 2 study of Glioblastoma that has completed, run by ImmunityBio. The registered enrollment target is 28 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02014844, a Phase 2 study of Glioblastoma, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
Conditions Studied
Interventions
- DRUG 250 mg/m2 aldoxorubicin
- DRUG 350 mg/m2 aldoxorubicin
Study Locations (4)
California
- City of Hope National Medical Center - Duarte
- Sarcoma Oncology Center - Santa Monica
Louisiana
- Ochsner Health System - New Orleans
Texas
- Texas Oncology-Austin Midtown - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02014844
The ClinicalTrials.gov registry entry for NCT02014844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (74% lower). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which 250 mg/m2 aldoxorubicin is the first listed.
NCT02014844 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT02014844 about?
NCT02014844 is a clinical study titled "Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma". This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
What is the current status of trial NCT02014844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2014-03. Estimated completion is 2016-12.
What conditions does trial NCT02014844 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02014844?
The interventions under investigation include: 250 mg/m2 aldoxorubicin (DRUG), 350 mg/m2 aldoxorubicin (DRUG).
Who is sponsoring clinical trial NCT02014844?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02014844 being conducted?
This trial has 4 study locations across California, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.